000			04761nam a22003015i 4500
001			402984
003			ES-MaUEC
005			20240528105948.0
007			cr nn 008mamaa
008			240214s2023 sz | o |||| 0|eng d
020			_a9783031468421
024	7		_a10.1007/978-3-031-46842-1 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRB1-214 _b2023 EB
245	0	0	_aPrecision Molecular Pathology of Aggressive B-Cell Lymphomas _cedited by Genevieve M Crane, Sanam Loghavi
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aMolecular Pathology Library _x1935-9888
505	0		_aSection I. Background -- Historical Perspectives in B-Cell Lymphoma Classification: From Hodgkin to WHO -- Revisions to the Classification of Aggressive B-Cell Lymphomas -- Section II. Methods -- Cytogenetics and FISH in Precision Molecular Pathology of Aggressive B-Cell Lymphomas -- Introduction to Next Generation Sequencing -- Next Generation Sequencing-Based Methods for the Detection of B-Cell Clonality -- Next Generation Sequencing Detection of Copy Number Variants and Translocations -- RNA-Seq and RNA Expression Profiling -- Flow Cytometry Applications in the Diagnosis and Classification of Aggressive B-Cell Lymphoma -- Section III. Molecular Characteristics of Specific Large B-Cell Lymphoma Subtypes -- High-Grade B-Cell Lymphomas -- Precision Medicine in Burkitt and Burkitt-Like Lymphomas -- Precision Medicine in Diffuse Large B-Cell Lymphoma -- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma -- Special Sites: Primary Mediastinal Large B-Cell Lymphoma, Primary CNS Diffuse Large B-Cell Lymphoma, and Primary Testicular Diffuse Large B-Cell Lymphoma -- Molecular Pathology of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type -- Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified -- Lymphomatoid Granulomatosis -- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma -- ALK Positive Large B-Cell Lymphoma -- HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / KSHV/HHV8-Positive Diffuse Large B-Cell Lymphoma -- Large B-Cell Lymphomas With IRF4 Rearrangements -- Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation and Fibrin-Associated Large B-Cell Lymphoma -- Section IV. Immune Deficiency Related Lymphoproliferative Disease -- Plasmablastic Lymphoma -- Genetic Landscape of Post-Transplant Lymphoproliferative Disorders -- Epstein-Barr Virus-Positive Mucocutaneous Ulcer -- Section V. Emerging Molecular Technologies -- Circulating Tumor DNA in Lymphoma.
520			_aWritten by experts in the field, Precision Molecular Pathology of Aggressive B-Cell Lymphomas contains the most recent revisions from the 5th Edition WHO and 2022 International Consensus Classification diagnostic categories and serves as an important resource for trainees, pathologists, haematologist/oncologists, other clinicians involved in lymphoma care and lymphoma researchers. It provides a comprehensive yet concise synthesis of emerging molecular advances that inform patient care and improve understanding of disease mechanisms. In addition, it provides the necessary background to how molecular techniques are performed to enable the reader to better interpret and critically evaluate relevant and emerging data. As part of the Molecular Pathology Library series, this book focuses specifically on aggressive B-cell lymphomas given the increasing relevance of molecular data for diagnosis and treatment of these disorders. This evidence-based text contains 25 chapters and is divided into 5 parts. Part 1 provides a brief history and background of aggressive B-cell lymphomas. Landmark events in their classification and treatment are given in order to place the substantial advances in the field in context. Part 2 reviews molecular pathology methods, including the increasing use of next generation sequencing techniques in clinical practice. Parts 3 and 4 focus on individual subtypes of aggressive B-cell lymphoma, including a summary of the diagnostic criteria and key pathologic and clinical features for each entity. Finally, Part 5 focuses on emerging molecular technologies that may significantly impact clinical practice. .
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-46842-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
988			_aSpringer_Medicine_2023
999			_c402984 _d402984